Find HSDB 4295 manufacturers, exporters & distributors on PharmaCompass

PharmaCompass

Synopsis

Synopsis

ACTIVE PHARMA INGREDIENTS

0

USDMF

US DMFs Filed

0

CEP/COS

CEP/COS Certifications

0

JDMF

JDMFs Filed

0

EU WC

EU WC

0

KDMF

KDMF

0

NDC API

NDC API

0

VMF

NDC API

API REF. PRICE (USD/KG)

$
$ 0

MARKET PLACE

0

FDF

0INTERMEDIATES

FINISHED DOSAGE FORMULATIONS

0

FDF Dossiers

FDF Dossiers

0

FDA Orange Book

FDA (Orange Book)

0

Europe

Europe

0

Canada

Canada

0

Australia

Australia

0

South Africa

South Africa

0

Listed Dossiers

Listed Dossiers

FDF Dossiers

DRUG PRODUCT COMPOSITIONS

REF. STANDARDS OR IMPURITIES

0

EDQM

0

USP

0

JP

0

Others

PATENTS & EXCLUSIVITIES

0

US Patents

0

US Exclusivities

0

Health Canada Patents

DIGITAL CONTENT

0

Data Compilation #PharmaFlow

0

Stock Recap #PipelineProspector

0

Weekly News Recap #Phispers

0

News #PharmaBuzz

GLOBAL SALES INFORMATION

US Medicaid

NA

Annual Reports

NA

Finished Drug Prices

NA

0RELATED EXCIPIENT COMPANIES

0EXCIPIENTS BY APPLICATIONS

Chemistry

Click the arrow to open the dropdown
read-moreClick the button for full data set
Also known as: 56-69-9, Dl-5-hydroxytryptophan, 5-hydroxy-dl-tryptophan, 2-amino-3-(5-hydroxy-1h-indol-3-yl)propanoic acid, 114-03-4, (+-)-5-hydroxytryptophan
Molecular Formula
C11H12N2O3
Molecular Weight
220.22  g/mol
InChI Key
LDCYZAJDBXYCGN-UHFFFAOYSA-N
FDA UNII
9181P3OI6N

HSDB 4295
The immediate precursor in the biosynthesis of SEROTONIN from tryptophan. It is used as an antiepileptic and antidepressant.
1 2D Structure

HSDB 4295

2 Identification
2.1 Computed Descriptors
2.1.1 IUPAC Name
2-amino-3-(5-hydroxy-1H-indol-3-yl)propanoic acid
2.1.2 InChI
InChI=1S/C11H12N2O3/c12-9(11(15)16)3-6-5-13-10-2-1-7(14)4-8(6)10/h1-2,4-5,9,13-14H,3,12H2,(H,15,16)
2.1.3 InChI Key
LDCYZAJDBXYCGN-UHFFFAOYSA-N
2.1.4 Canonical SMILES
C1=CC2=C(C=C1O)C(=CN2)CC(C(=O)O)N
2.2 Other Identifiers
2.2.1 UNII
9181P3OI6N
2.3 Synonyms
2.3.1 MeSH Synonyms

1. 5 Hydroxytryptophan

2. 5-htp

3. 5-hydroxy- Tryptophan

4. Hydroxytryptophan

5. Oxitriptan

6. Oxytryptophan

7. Tryptophan, 5 Hydroxy

8. Tryptophan, 5-hydroxy-

2.3.2 Depositor-Supplied Synonyms

1. 56-69-9

2. Dl-5-hydroxytryptophan

3. 5-hydroxy-dl-tryptophan

4. 2-amino-3-(5-hydroxy-1h-indol-3-yl)propanoic Acid

5. 114-03-4

6. (+-)-5-hydroxytryptophan

7. Dl-hydroxytryptophan

8. Dl-5-htp

9. 5-htp

10. 5-hydroxytryptophan Dl-form

11. H-dl-trp(5-oh)-oh

12. D,l-5-hydroxytryptophan

13. Nsc-92523

14. (+/-)-5-hydroxytryptophan

15. 5-hydroxytryptophan (5-htp)

16. Chebi:28171

17. 9181p3oi6n

18. Mfcd00005651

19. Dl-pretonine

20. 72572-98-6

21. Dl-oxitriptan

22. 5-hydroxy Tryptophan

23. Usaf Cb-96

24. 5-hydroxytryptophan, Dl-

25. 5-hydroxytryptophan L Form

26. Hsdb 4295

27. Dl-5-hydroxytryptophane

28. Nci-c56644

29. Tryptophan, 5-hydroxy-, Dl

30. 5-22-14-00278 (beilstein Handbook Reference)

31. Einecs 200-284-8

32. Tryptophan, 5-hydroxy-, L-

33. Nsc 92523

34. Brn 0088199

35. Dl-tryptophan, 5-hydroxy-

36. Unii-9181p3oi6n

37. Mfcd00064341

38. 5-hydroxyltryptophan

39. 5-hydroxytryptophan #

40. H-l-trp(5-oh)-oh

41. 5-hydroxytryptophan(5-htp)

42. Schembl43242

43. Mls006011926

44. 2-amino-3-(5-hydroxy-1h-indol-3-yl)propanoicacid

45. (.+-.)-5-hydroxytryptophan

46. Chembl162789

47. 5-hydroxytryptophan, Aldrichcpr

48. Schembl19871232

49. 5-hydroxytryptophan [mi]

50. Dtxsid50859863

51. Hms3372g05

52. Hms3656m11

53. Hms3884h15

54. Wln: T56 Bmj D1yzvq Gq

55. 5-hydroxytryptophan [hsdb]

56. Hy-n0122

57. Nsc92523

58. Bbl012270

59. S2374

60. Stk803137

61. Akos003382640

62. Akos016050369

63. Ccg-235444

64. Ncgc00015526-02

65. Ncgc00015526-04

66. Ac-13632

67. Ac-23979

68. Smr000326745

69. Sy030569

70. Sy048412

71. Vs-03256

72. Db-051092

73. A2320

74. Cs-0007832

75. Ft-0620484

76. Ft-0620490

77. Ft-0620491

78. Ft-0620498

79. Ft-0627633

80. Sw219417-1

81. 56h699

82. C01017

83. Dl-2-amino-3-(5-hydroxyindolyl)propionic Acid

84. H-8280

85. N88462

86. Sr-01000003309

87. Q-102914

88. Sr-01000003309-1

89. Q27103541

2.4 Create Date
2005-03-27
3 Chemical and Physical Properties
Molecular Weight 220.22 g/mol
Molecular Formula C11H12N2O3
XLogP3-1.2
Hydrogen Bond Donor Count4
Hydrogen Bond Acceptor Count4
Rotatable Bond Count3
Exact Mass220.08479225 g/mol
Monoisotopic Mass220.08479225 g/mol
Topological Polar Surface Area99.3 Ų
Heavy Atom Count16
Formal Charge0
Complexity272
Isotope Atom Count0
Defined Atom Stereocenter Count0
Undefined Atom Stereocenter Count1
Defined Bond Stereocenter Count0
Undefined Bond Stereocenter Count0
Covalently Bonded Unit Count1
4 Drug and Medication Information
4.1 Therapeutic Uses

5-HTP has shown some usefulness in some conditions characterized, in part, by serotonin deficits, principally depression. It has also been shown to be useful in some with obesity, insomnia, fibromyalgia and chronic tension headache.

Physicians Desk Reference (PDR) for Nutritional Supplements 1st ed, Medical Economics, Thomson Healthcare; Montvale, NJ p.4 (2001)


It has been long known that brain serotonin systems contribute to the modulation of food intake and satiety. An increase of intrasynaptic serotonin tends to reduce food consumption. Thus, one might consider that individuals taking 5-HTP might experience increase satiety and weight loss over a period of time. There are few studies on the effects of 5-HTP on obesity and they suggest an anorectic effect of 5-HTP.

Coates, P.M., Blackman, M.R., Cragg, G.M., Levine, M., Moss, J., White, J.D. (Ed), Encyclopedia of Dietary Supplements. Marcel Dekker, New York, NY, p. 350 (2005)


There is some evidence that 5-HTP ... can improve postural equilibrium, dysarthria in patients with various inherited and acquired cerebellar ataxias, and particularly in those with lesions located precisely in the anterior lobe vermis. Improvements in coordination have been reported in patients with Friedreich"s ataxia; however, the effect is only partial and not clinically major.

Coates, P.M., Blackman, M.R., Cragg, G.M., Levine, M., Moss, J., White, J.D. (Ed), Encyclopedia of Dietary Supplements. Marcel Dekker, New York, NY, p. 352 (2005)


Exptl Ther: Rats of the Dahl salt-sensitive (DS) and Dahl salt-resistant (DR) strains were placed on a 4% NaCl diet and blood pressures were monitored. Chronic subcutaneous infusion L-5-hydroxytryptophan (L-5-HTP, 12.6 mg/day) by osmotic minipumps significantly decreased the elevated systolic blood pressure of DS rats on a 4% NaCl diet. Blood pressures of DR rats were unaffected by treatment with L-5-HTP. Cardiac hypertrophy was associated with Dahl salt-induced hypertension. However, treatment with L-5-HTP failed to reduce the weight of the heart significantly. These results suggest that chronic administration of L-5-HTP was effective in reducing the elevated blood pressure in the DS model. The specific mechanisms by which L-5-HTP reduces the elevated blood pressure in DS rats is not clear and remains for further study.

PMID:1829234 Baron A et al; Pharmacology 42 (1): 15-22 (1991)


For more Therapeutic Uses (Complete) data for 5-HYDROXYTRYPTOPHAN (6 total), please visit the HSDB record page.


4.2 Drug Warning

Other reported side effects, include nausea, diarrhea, loss of appetite, vomiting and difficult breathing. Neurological side effects, including dilation of the pupils, abnormally sensitive reflexes, loss of muscle coordination and blurring of vision, have been reported in those taking large doses of 5-HTP. Cardiac dysrhythmias have also been reported.

Physicians Desk Reference (PDR) for Nutritional Supplements 1st ed, Medical Economics, Thomson Healthcare; Montvale, NJ p.5 (2001)


Eosinophilia and eosinophilia-myalgia syndrome (EMS) have been reported in those taking 5-HTP. The eosinophilia myalgia syndrome is similar to that caused by L-tryptophan and was linked to contaminants in the 5-HTP preparation, rather than 5-HTP itself. Changing the 5-HTP lot in one group of patients resolved the eosinophilia. A scleroderma-like skin condition has been reported in some taking a combination of 5-HTP and carbidopa.

Physicians Desk Reference (PDR) for Nutritional Supplements 1st ed, Medical Economics, Thomson Healthcare; Montvale, NJ p.5 (2001)


5-HTP should be avoided by pregnant women and nursing mothers.

Physicians Desk Reference (PDR) for Nutritional Supplements 1st ed, Medical Economics, Thomson Healthcare; Montvale, NJ p.5 (2001)


5-HTP should be avoided by those with ischemic heart disease (history of myocardial infarction, angina pectoris, documented silent ischemia), coronary artery spasm (e.g., Prinzmetal's angina), uncontrollable hypertension and any other significant cardiovascular disease.

Physicians Desk Reference (PDR) for Nutritional Supplements 1st ed, Medical Economics, Thomson Healthcare; Montvale, NJ p.4 (2001)


For more Drug Warnings (Complete) data for 5-HYDROXYTRYPTOPHAN (8 total), please visit the HSDB record page.


5 Pharmacology and Biochemistry
5.1 MeSH Pharmacological Classification

Antidepressive Agents, Second-Generation

A structurally and mechanistically diverse group of drugs that are not tricyclics or monoamine oxidase inhibitors. The most clinically important appear to act selectively on serotonergic systems, especially by inhibiting serotonin reuptake. (See all compounds classified as Antidepressive Agents, Second-Generation.)


5.2 Absorption, Distribution and Excretion

The immediate precursor in the serotonin synthetic route, 5-hydroxytryptophan (5-HTP), labeled with 11C in the beta position, has become available for studies using positron emission tomography (PET) to examine serotonin formation in human brain. Normalized uptake and intracerebral utilization of tracer amounts of (beta-11C)5-HTP were studied twice in six healthy male volunteers, three of them before and after pharmacological pretreatments ... Pretreatments with benserazide, p-chlorophenylalanine (PCPA), and unlabeled 5-HTP all significantly increased uptake of (beta-11C)5-HTP. The utilization rates in both striatal and frontal cortex were higher than those in the surrounding brain, indicating that PET studies using (beta-11C)5-HTP as a ligand quantitate selective processes in the utilization of 5-HTP.

PMID:1292039 Reibring L et al; Psychiatry Res 45(4): 215-25 (1992)


The efficiency of absorption of 5HTP, as well as its decarboxylation product serotonin, is approximately 47% to 84%. Absorption of 5-HTP occurs by an active transport process. 5-HTP is transported by the portal circulation to the liver where approximately 25% of an administered dose is metabolized ... . 5-HTP that is not metabolized in the liver is transported by the general circulation to the various tissues of the body, including the brain. 5-HTP readily crosses the blood-brain barrier, and is converted to serotonin in brain cells.

Physicians Desk Reference (PDR) for Nutritional Supplements 1st ed, Medical Economics, Thomson Healthcare; Montvale, NJ p.4 (2001)


5.3 Metabolism/Metabolites

5-HTP is transported by the portal circulation to the liver where approximately 25% of an administered dose is metabolized via vitamin B6-dependent L-aromatic amino acid decarboxylase to 5-hydroxytryptamine (5-HT) /serotonin/. 5-HT is subsequently metabolized to 5-hydroxyindole acetaldehyde which is rapidly metabolized to 5-hydroxyindole acetaldehyde which is rapidly metabolized to 5-hydroxyindoleacetic acid (5-HIAA).

Physicians Desk Reference (PDR) for Nutritional Supplements 1st ed, Medical Economics, Thomson Healthcare; Montvale, NJ p.4 (2001)


5.4 Mechanism of Action

The possible analgesic effect of 5-HTP may be accounted for, in part, by its conversion to serotonin. 5-HTP has also been found to increase plasma beta-endorphin and platelet met-enkephalin levels, which may signify a reinforcing effect upon an endogenous analgesic effect.

Physicians Desk Reference (PDR) for Nutritional Supplements 1st ed, Medical Economics, Thomson Healthcare; Montvale, NJ p.3 (2001)


The mechanism of the possible antidepressant activity of 5-HTP is accounted for by its conversion to the neurotransmitter serotonin which plays a central role in the affective state. Antidepressants may work by either binding to one or more of the family of serotonin 5-HT receptors (5-HT1 - 5-HT7) or by inhibiting the reuptake of serotonin. ...

Physicians Desk Reference (PDR) for Nutritional Supplements 1st ed, Medical Economics, Thomson Healthcare; Montvale, NJ p.3 (2001)


Market Place

Do you need sourcing support? Ask us

ABOUT THIS PAGE

Ask Us for Pharmaceutical Supplier and Partner
Ask Us, Find A Supplier / Partner
No Commissions, No Strings Attached, Get Connected for FREE

What are you looking for?

How can we help you?

The request can't be empty

Please read our Privacy Policy carefully

You must agree to the privacy policy

The name can't be empty
The company can't be empty.
The email can't be empty Please enter a valid email.
The mobile can't be empty